Browse through our GU Cast library going back to March 2020
Our Library
Augerlicious! Terbium-161's double punch to prostate cancer. ProsTIC-PCF-GU Cast Global Webinar
Another of our deep-in-the-weeds theranostic webinars in conjunction with our friends at ProsTiC, and the Prostate Cancer Foundation. This one focussed on Terbium-161, a very exciting new option in metastatic prostate cancer. Your hosts are Dr Renu Eapen and Professor Michael Hofman, with Dr Howard Soule and Dr Andrea Miyahira from the Prostate Cancer Foundation. Special guests include Dr James Buteau (Peter Mac, Melbourne, Australia), Dr Alin Chirindel (Universitätsspital Basel), Prof Dr Samer Ezziddin (Saarland University Hospital, Germany) and Prof. Cristina Müller (Paul Scherrer Institute, Switzerland)
And in ADDITION....Lu-PSMA improves outcomes in mHSPC | With Scott Tagawa and Michael Hofman
Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25.
ENZA-P Big news Update: LuPSMA and enza improves overall survival
A breaking news podcast from ASCO GU in San Francisco! Prof Louise Emmett (St Vincent's, Sydney), has just read out the latest update from the ENZA-P trial (and simultaneous publication in Lancet Oncology), reporting that the combination of LuPSMA and enzalutamide improves overall survival when compared with enzalutamide alone, in men with poor prognosis mCRPC. Big news!!
Future-gazing radioligand therapy in prostate cancer | With Oliver Sartor and Michael Hofman
Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer.
LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman
Exclusive discussion with Arun Azad and Michael Hofman to celebrate Arun'z presentation of UpFront PSMA at ESMO24 today. Simultaneous publication in Lancet Oncology. This is a Themed Podcast supported by our Silver Partners, Novartis.
ProsTIC24 PSMA Theranostics Conference Highlights
Educational and entertaining GU Cast Conference Highlights from the ProsTIC24 Preceptorship in Melbourne.
ADT and cardiac risks (and how I sold my company for $1.4bn)
We loved having Neil Fleshner in the studio!!
Bringing LuPSMA earlier | ProsTIC/PCF/ICIS Global Webinar
Another one of our PSMA theranostics webinars in collaboration with ProsTIC, the PCF, and the International Cancer Imaging Society. Fabulous deep dive into earlier use of LuPSMA